Compare ONDS & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONDS | LQDA |
|---|---|---|
| Founded | 2014 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.5B |
| IPO Year | N/A | 2018 |
| Metric | ONDS | LQDA |
|---|---|---|
| Price | $8.46 | $32.86 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | $9.60 | ★ $37.40 |
| AVG Volume (30 Days) | ★ 118.3M | 1.8M |
| Earning Date | 11-13-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $24,748,922.00 | ★ $69,216,000.00 |
| Revenue This Year | $406.15 | $904.79 |
| Revenue Next Year | $219.04 | $188.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 208.40 | ★ 343.41 |
| 52 Week Low | $0.57 | $10.37 |
| 52 Week High | $11.70 | $35.54 |
| Indicator | ONDS | LQDA |
|---|---|---|
| Relative Strength Index (RSI) | 53.96 | 59.75 |
| Support Level | $7.32 | $30.50 |
| Resistance Level | $9.86 | $35.54 |
| Average True Range (ATR) | 1.07 | 1.71 |
| MACD | 0.13 | 0.07 |
| Stochastic Oscillator | 62.74 | 63.62 |
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.